USX:GHDX - Genomic Health Inc (USD 63.44) Genomic Health Inc
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance
Note: This stock seems to be inactive

USD 63.44    -0.440 (-0.69%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

7 Nov 2019


7 Nov 2019

Day Change: -0.440 (-0.69%)

52 Wk Range: 50.77 - 86.7

Day's Range: 62.74 - 64.57

Last Volume: 12,537,091

Current Yield: 0%

Projected Yield: 0%

Open: USD 63.88

14 Nov 2019

Metric GHDX S.Median
Beta 1.27 0.57
VaR 27.29 40.71
E.Shortfall 34.48 63.49
Liquidity 70.74K 13.89K


7 Nov 2019

PE: 43.674

Market Cap: 2.5B

Price Over Book: 7.074

Price Over Sales: 5.59

Return On Assets: 12.3%

Return On Equity: 16.2%

Price Over NAV: [Friends Only]


CEO: Kimberly J. Popovits

Headquarters: REDWOOD CITY

Employees: 829

Sector: Health Technology

Industry: Medical Specialties

Useful Links


Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has a collaboration agreement with Epic Sciences, Inc. The company was founded in 2000 and is based in Redwood City, California.